VIR at a discount
VIR has a couple of interesting products testing in the pipeline.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
The one that caused the spike in Jan is for hepatitis B treatment.
And the selloff today is caused by the pause in the enrollment of late-stage trial testing of their Covid19 antibody.
So it seems it is safe to assume that it will return above previous resistance of 53. With 80's as a first target, and then, potentially, to ATH.
Not
Nice opening todayNot taking profit, expecting higher
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.